RT Journal Article
SR Electronic
T1 Keynote 48: Is it really for everyone?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.18.20070888
DO 10.1101/2020.04.18.20070888
A1 Schoenfeld, Jonathan D.
A1 Fell, Geoffrey
A1 Haddad, Robert I.
A1 Trippa, Lorenzo
YR 2020
UL http://medrxiv.org/content/early/2020/04/24/2020.04.18.20070888.abstract
AB Burtness et al. recently published the landmark Keynote-48 study, demonstrating a survival benefit for pembrolizumab monotherapy and pembrolizumab/chemotherapy, compared with cetuximab/chemotherapy, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). These data are impactful and practice-changing, and have rapidly been adopted in practice, with increasing numbers of HNSCC patients receiving either pembrolizumab monotherapy, or pembrolizumab / chemotherapy, in the first line recurrent / metastatic setting. Pembrolizumab was approved as a single agent for patients whose tumors express PD□L1 (Combined Positive Score [CPS] ≥1), while pembrolizumab / chemotherapy was approved for use in the United States for all patients irrespective of PD-L1 expression.Competing Interest StatementJDS reports research support paid to the institution: Merck, BMS, Regeneron; Consulting / Scientific Advisory Board / Travel fees: Debiopharm, BMS, Nanobiotix, Tilos, AstraZeneca, LEK, Catenion, ACI Clinical, Immunitas; Expert witness fees. RIH reports consulting for BMS, Merck, AstraZeneca, Pfizer, GSK, Genentech, Celgene and Bayer and Reseaerch Support from GSK, Merck, BMS, Pfizer, AstraZeneca, Genentech and Kura.Funding StatementNo external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable